Wall Street brokerages expect Marker Therapeutics, Inc. (NASDAQ:MRKR) to announce ($0.16) earnings per share (EPS) for the current fiscal quarter, according to Zacks. Zero analysts have issued estimates for Marker Therapeutics’ earnings. The lowest EPS estimate is ($0.17) and the highest is ($0.15). Marker Therapeutics posted earnings per share of ($0.11) during the same quarter last year, which would suggest a negative year over year growth rate of 45.5%. The firm is expected to report its next quarterly earnings report on Thursday, March 11th.
On average, analysts expect that Marker Therapeutics will report full-year earnings of ($0.59) per share for the current fiscal year, with EPS estimates ranging from ($0.60) to ($0.58). For the next year, analysts expect that the company will post earnings of ($0.68) per share, with EPS estimates ranging from ($0.69) to ($0.66). Zacks Investment Research’s EPS calculations are an average based on a survey of research firms that follow Marker Therapeutics.
Several research analysts have issued reports on the company. Oppenheimer restated a “buy” rating and set a $8.00 target price on shares of Marker Therapeutics in a research report on Monday, November 23rd. Zacks Investment Research upgraded Marker Therapeutics from a “sell” rating to a “hold” rating in a research report on Tuesday, January 5th. Three equities research analysts have rated the stock with a hold rating and three have given a buy rating to the stock. The company has an average rating of “Buy” and a consensus price target of $7.50.
Shares of MRKR stock opened at $2.65 on Thursday. Marker Therapeutics has a 12-month low of $1.32 and a 12-month high of $3.77. The stock’s 50-day moving average price is $2.24 and its 200-day moving average price is $1.77. The stock has a market capitalization of $127.27 million, a price-to-earnings ratio of -4.82 and a beta of 1.27.
Marker Therapeutics Company Profile
Marker Therapeutics, Inc, a clinical stage immuno-oncology company, engages in the development and commercialization of various T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. Its MultiTAA-specific T cell technology is based on the expansion of non-engineered tumor-specific T cells that recognize tumor associated antigens and kill tumor cells expressing those targets.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Marker Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Marker Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.